Not Signed In - Acuity Pharmaceuticals Reports Positive Initial Phase II Results For Bevasiranib (Cand5) In Wet AMD
Fri, 02 Jun 2006 06:00 AM EST
... AcuityPharmaceuticals, an ophthalmic pharmaceutical company, today announced thatits lead clinical compound bevasiranib sodium, formerly known as Cand5,appeared safe and showed clinical evidence of efficacy in the first resultsfrom the Phase II C.A.R.E.(TM) trial for the treatment of wet AMD. [click link for full article] ...
Related Topics
- Age-Related Macular Degeneration
- Wet Lung
- Clinical Trials
- Nystatin and Triamcinolone
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Tb
- Macular Degeneration
- Brain injury that results in physical, emotional, or intellectual changes or deficits
- Well Baby Reports
- Tuberculosis Surveillance Reports
- Chronic Disease At A Glance Reports
- Chronic Disease Notes And Reports
- Sexually Transmitted Disease Surveillance Reports
- Vaccine Safety and Adverse Event Reports
- Kniest dysplasia
- Ampicillin
- HLA-B27
- Triple Screen
- Juvenile Diabetes
email this page
print this page
bookmark this page
feedback on this page
